Andarix Pharmaceuticals CEO Chris Adams will chair a session at the upcoming Target Selection and Drug Design Conference in Boston, bringing together industry experts to explore innovative approaches in radiopharmaceutical research and development.
The conference, scheduled for February 25-27, 2025, will focus on advanced mechanisms in radiobiological research, including strategies for targeting therapies across various molecular platforms. Participants will examine radiation absorption techniques, drug design methodologies, and emerging technologies in cancer treatment.
The event represents a critical opportunity for professionals in medicinal chemistry, radiobiology, pharmacology, and computational biology to share insights into novel drug development strategies. Attendees will gain practical perspectives on target selection, drug rationale, and commercial considerations in the rapidly evolving radiopharmaceutical landscape.
Andarix Pharmaceuticals, known for developing personalized cancer therapies, brings significant expertise to the conference. The company's proprietary somatostatin peptide conjugate technology shows particular promise for targeting lung, pancreatic, neuroendocrine, and other cancer types, where somatostatin receptors are highly prevalent.
By convening experts across multiple disciplines, the conference aims to accelerate innovation in targeted cancer therapies, potentially improving patient outcomes and advancing precision medicine approaches.
